Meridian Bioscience Inc VIVO
We take great care to ensure that the data presented and summarized in this overview for MERIDIAN BIOSCIENCE INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VIVO
View all-
Havens Advisors LLC New York, NY26.8KShares$02.29% of portfolio
-
Telemetry Investments, L.L.C. New York, NY20.3KShares$01.06% of portfolio
-
Advisor Partners LLC Walnut Creek, CA19.7KShares$00.04% of portfolio
-
Sarissa Consulting LLC Santa Monica, CA18.3KShares$00.59% of portfolio
-
Brinker Capital Investments, LLC16KShares$00.01% of portfolio
-
Hightower 6 M Holding, LLC11.8KShares$00.03% of portfolio
-
Trustcore Financial Services, LLC300Shares$00.0% of portfolio
-
Wipfli Financial Advisors Llc,271Shares$00.0% of portfolio
-
Huntington National Bank Columbus, OH1Shares$00.0% of portfolio
-
Concourse Financial Group Securities, Inc. Birmingham, AL0Shares$00.0% of portfolio
Latest Institutional Activity in VIVO
Top Purchases
Top Sells
About VIVO
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H. pylori under the BreathID and BreathTek brand. This segment also offers respiratory illness assays, such as tests Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry products for LeadCare test kits for the detection of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.
Insider Transactions at VIVO
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jan 31
2023
|
John Mc Cune Rice Jr. Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
27,449
-100.0%
|
-
|
Jan 31
2023
|
Catherine Sazdanoff Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
16,424
-100.0%
|
-
|
Jan 31
2023
|
Felicia Williams Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
10,274
-100.0%
|
-
|
Jan 31
2023
|
James M. Anderson Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
5,000
-100.0%
|
-
|
Jan 31
2023
|
James M. Anderson Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
28,224
-100.0%
|
-
|
Jan 31
2023
|
Anthony P Bihl Iii Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
15,408
-100.0%
|
-
|
Jan 31
2023
|
Dwight E Ellingwood Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
17,290
-100.0%
|
-
|
Jan 31
2023
|
John Mc Ilwraith Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
21,724
-100.0%
|
-
|
Jan 31
2023
|
Tony Serafini Lamanna Executive VP-Diagnostics |
SELL
Sale (or disposition) back to the issuer
|
Direct |
43,338
-100.0%
|
-
|
Jan 31
2023
|
Tony Serafini Lamanna Executive VP-Diagnostics |
BUY
Grant, award, or other acquisition
|
Direct |
7,945
+15.49%
|
-
|
Jan 31
2023
|
Lourdes Weltzien Executive VP, Life Science |
SELL
Sale (or disposition) back to the issuer
|
Direct |
86,045
-100.0%
|
-
|
Jan 31
2023
|
Lourdes Weltzien Executive VP, Life Science |
BUY
Grant, award, or other acquisition
|
Direct |
7,945
+8.45%
|
-
|
Jan 31
2023
|
Andrew S. Kitzmiller Executive Vice President & CFO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
19,473
-100.0%
|
-
|
Jan 31
2023
|
Andrew S. Kitzmiller Executive Vice President & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
7,945
+28.98%
|
-
|
Jan 31
2023
|
John P. Kenny Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
267,651
-100.0%
|
-
|
Jan 31
2023
|
John P. Kenny Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
47,060
+14.95%
|
-
|
Jan 31
2023
|
Julie Diana Smith Sr VP, Controller, PAO |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
25,600
-100.0%
|
-
|
Jan 31
2023
|
Julie Diana Smith Sr VP, Controller, PAO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
32,708
-100.0%
|
-
|
Jan 31
2023
|
Julie Diana Smith Sr VP, Controller, PAO |
BUY
Grant, award, or other acquisition
|
Direct |
2,648
+7.49%
|
-
|
Jan 06
2023
|
James M. Anderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,500
+23.15%
|
$170,000
$20.38 P/Share
|